trending Market Intelligence /marketintelligence/en/news-insights/trending/WuRSy7GJv36tHjdDRuNmQg2 content esgSubNav
In This List

Abcam completes €120M acquisition of businesses from Expedeon

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Abcam completes €120M acquisition of businesses from Expedeon

Abcam PLC has completed its acquisition of the proteomics and immunology businesses of Expedeon AG.

Abcam CEO Alan Hirzel said acquiring the German biotechnology company adds its product and technology portfolio to Abcam's antibody research and tools.

In November, Cambridge, England-based Abcam announced its intent to acquire Expedeon's three proteomics and immunology businesses — Expedeon Ltd., Innova Biosciences Ltd. and TGR BioSciences— for €120 million in cash.

In January 2019, Abcam bought antibodies developer Calico Biolabs Inc. to expand its production capabilities.